July 15, 2024

Medical Disposables and Supplies Limited (MDS) reported a 2% decrease in Revenue totalling $3.71 billion for the twelve months ended March 31, 2024, compared to $3.77 billion in the corresponding period last year. Revenue for the fourth quarter increased 1% to close at $1.02 billion, compared to $1.01 billion for the comparable quarter of 2023.

Cost of Sales amounted to $3.00 billion (2023: $2.76 billion), an increase of 9% year over year. Gross Profit decreased by 30% to $713.90 million compared to $1.01 billion for the twelve months ended March 31, 2023. The company booked a gross Profit of $47.07 million for the fourth quarter versus $260.49 million reported for the similar quarter of 2023.

Administrative expenses increased by 4% to close at $473.63 million (2023: $456.39 million) while Selling and promotional costs increased by 13% from $327.11 million in 2023 to $370.71 million in the period under review. As a result, total operating expenses for the twelve months ended March 31, 2024, amounted to $905.16 million, a 9% increase relative to $828.10 million reported in 2023.

Operating Loss for the twelve months ended March 31, 2024, amounted to $175.27 million relative to an operating profit of $195.72 million reported in 2023. Operating Loss for the fourth quarter amounted to a loss of $213.30 million (2023: operating profit of $27.54 million).
Finance income totalled $272,272, an 89% decrease from last year’s period. (2023: $2.47 million) while Finance costs totalled $159.93 million, a 54% increase from last year’s corresponding period  (2023: $104.17 million).

Loss before tax for the twelve months ended March 31, 2024, amounted to $320.51 million relative to profit before tax, $96.72 million reported in 2023, while loss before tax for the fourth quarter amounted to $231.78 million (2023: profit before tax of $14.54 million). Tax credit for the twelve months ending March 31, 2024, amounted to $4.55 million (2023: tax charges of $16.52 million). Loss for the year for the twelve months amounted to $315.96 million from a profit of $80.20 million reported in 2023. The fourth quarter’s loss amounted to $227.41 million (2023: net profit of $12.39 million).
Consequently, Loss Per Share for the twelve months amounted to $1.11 (2023: EPS: $0.27), while Loss Per Share for the quarter totalled $0.78 (2023: EPS: $0.05). The number of shares used in these calculations was 263,157,895.

Notably, MDS’s stock closed the trading period on July 15, 2024, at $2.52.

Balance Sheet Highlights:

The company’s assets totalled $2.75 billion, a 13% decrease from $3.03 billion in 2023. This significant decline in total assets is primarily due to a 17% year-over-year decline in ‘Cash and cash equivalents,’ which ended the fiscal year at $118.05 million. ‘Property, plant and equipment’ also saw a 3% year-over-year decline, closing the year at $759.42 million, and ‘Inventories’ represented a 25% year-over-year decline, ending the fiscal year at $1.12 billion. Shareholder’s equity was $769.13 million (2023: $1.06 billion), representing a book value per share of $2.92 (2023: $4.03). 28% year-over-year decline. The decline in shareholders’ equity results from the company’s loss over the fiscal year, both in its operational business and non-controlling interests. The “Retained profits” account represented the most significant loss with a 35% year-over-year decline, closing the fiscal year at $552.77 million (2023: $844.86 million).

Disclaimer:

Analyst Certification – The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.

Company Disclosure – The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein